

Preclinical Development of an Aptamer-Based Anti-Cancer Drug Targeting ALCAM



ONCOLOGY	Candidate
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Ovarian cancer, Metastatic cancer
Target	ALCAM
MoA(Mechanism of Action)	<p>HC-101 is a dual-function ApDC that:</p> <ul style="list-style-type: none"> • Inhibits intracellular signal transduction pathways critical for the survival of metastatic cancer cells • Delivers a cytotoxic payload directly to target cells, inducing apoptosis with high precision
Competitiveness	<ul style="list-style-type: none"> • Metastatic cancer-specific recognition aptamer • Deep tumor penetration and rapid clearance lead to potent efficacy with reduced systemic toxicity
Development Stage	Candidate
Route of Administration	I.V

Any unauthorized distribution or reproduction of this material is strictly prohibited.